Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

brain cancer.

Other Developments

-- Avid Bioservices became the first U.S. pre-approved contract manufacturer for licensees of the DSM Biologics and Crucell PER.C6(R) cell line, a proprietary high yield cell line with important advantages over other approaches.

-- Received a Staff Determination letter from the Nasdaq Stock Market indicating that the company was not in compliance with the $1.00 minimum bid price requirement for continued listing. On September 4, 2008, Peregrine attended an oral hearing with an independent Nasdaq Panel and Peregrine requested an additional 180 days to regain compliance, or until January 20, 2009. The final written decision from Nasdaq is expected within 30 days of the hearing date.

Conference Call

The company will host a conference call today, September 9, 2008 at 11:30 a.m. EDT/8:30 a.m. PDT to discuss its First Quarter FY 2009 financial results.

To listen to a live broadcast of the call over the Internet or to review the archived call, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for approximately 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through September 16, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... GEA Niro Soavi the leader in ... the PandaPLUS 2000, which is ideal for new applications ... cell disruption . This compact laboratory homogenizer is the ... food, food additives and ingredients as well as for ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting ... brand-neutral, independent consultants, Protocol Networks has recently announced its ... the years, his company has attracted several clients in ... as well as others. With the success of these ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... Research, a,global provider of pharmaceutical competitive intelligence and market,research, ... for,pharma and biotech companies with a stake in the ... Thought Leader Insight &,Analysis -- Parkinson,s Disease, is based ... (6) and Europe (3). , ...
... SAN DIEGO, Dec. 2 The Patient,Advocate Foundation (PAF), ... announce the launch of the Lymphedema CareLine (LCL). PAF, ... designed to provide information and assistance to breast cancer,patients ... side effects such as,lymphedema (swelling due to blockage in ...
... China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical, Co., Inc., ... traditional Chinese medicine ("TCM") based in Chengdu, China,today ... marketing strategy to,categorize both distributors and hospital clients ... and marketing structure. , ...
Cached Biology Technology:New Report Provides Expert Analysis of Recent Advances and Setbacks in Parkinson's Disease Drug Development 2New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema 2New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema 3Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth 2Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth 3
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been here before: ... can,t remember your password, site key or the answer to your ... teacher? Today, Hoyos Labs , a digital ... put an end to the frustration that comes with usernames, passwords ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced plans ... Medicine. Funding for this $50 million capital project is part ... next summer. The medical education building will ... Company complex, adjacent to 525@vine in Wake Forest Innovation Quarter. ...
(Date:12/10/2014)... 08, 2014 Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... Market in Japan 2014-2018" report to their offering. ... The integration of biometrics and smart cards for projects ... license is one of the major trends witnessed in ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... the fact that they both infect the liver, the ... little in common. The two are far apart genetically, ... A spreads through the consumption of fecal particles from ... example), but hepatitis C is generally transmitted only by ...
... take concerted action to ensure that people who are at ... according to the authors of a new report published today ... shows that influenza epidemics are associated with a rise in ... the heart attacks that result in death. , However, only ...
... whose brain cells respond to a flash of light are ... and may ultimately yield a better understanding of how the ... and the Howard Hughes Medical Institute have engineered a strain ... light. This was accomplished by inserting into the cells a ...
Cached Biology News:Researchers find hepatitis A and hepatitis C attack same protein to block immune defenses 2New research shows that flu is a trigger of heart attacks 2New research shows that flu is a trigger of heart attacks 3New research shows that flu is a trigger of heart attacks 4Scientists to track impact of Asian dust and pollution on clouds, weather, climate change 2Scientists to track impact of Asian dust and pollution on clouds, weather, climate change 3
... Experion Pro260 analysis kit for 10 chips ... perform protein analysis with the Experion automated ... microfluidic chips, 3 x 520 microliters Pro260 ... Pro260 ladder (10-260 kD), 400 microliters Pro260 ...
Experion Pro260 chips are the microfluidic chips used to perform protein analysis with the Experion automated electrophoresis system. Each chip has the capacity to run 10 protein samples. Supplied as...
... LabChip 3000 drug discovery system miniaturizes, ... assays. Using LabChip technology, the ... a serial, continuous flow fashion. LabChip ... of results exceeds what is achievable ...
... particles in the submicron range are part ... measurement and control of particle size is ... that can reliably detect the component populations ... Submicron Particle Size Analyzer uses Photon Correlation ...
Biology Products: